Other research analysts have also recently issued reports about the stock. UBS Group set a CHF 89 target price on shares of Novartis and gave the company a neutral rating in a report on Monday, November 25th. Deutsche Bank set a CHF 96 price target on shares of Novartis and gave the company a neutral rating in a research report on Thursday, January 9th. Jefferies Financial Group set a CHF 105 price target on Novartis and gave the stock a buy rating in a research note on Tuesday, December 17th. JPMorgan Chase & Co. set a CHF 91 price target on Novartis and gave the stock a sell rating in a report on Monday, January 6th. Finally, Goldman Sachs Group set a CHF 105 price target on Novartis and gave the stock a buy rating in a report on Monday, December 16th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of CHF 94.27.
Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.